Hutch News

Hutch News

Stories tagged 'acute myeloid leukemia'

Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal

T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers

April 16, 2018 | By Rachel Tompa / Fred Hutch News Service

In an effort to improve the efficacy of immunotherapy for solid tumors, Fred Hutch researchers have engineered a new type of protein that can rewire a 'kill switch' to stimulate T cells' activity instead.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


Unique set of tissue samples ‘ready to teach’ lessons about pediatric leukemia

Hutch-based repository leads to lifesaving treatments for young cancer patient

Aug. 29, 2017 | By Sabrina Richards / Fred Hutch News Service

A unique, Hutch-based repository of tissue samples ‘ready to teach’ lifesaving lessons about childhood leukemia.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.